Embed Size (px)
Citation preview
PHARMACEUTICAL HUB SWITZERLANDBASEL REGION
Preface 4
Pharmaceutical Industry in Switzerland 6Swiss Pharma Clusters 8Growth Driver Pharmaceuticals 10
Basel Region 20Innovation Capacity 24Inward Investment Factors 30Outlook 38
Company Profiles 40Glossary 46
3
TABLE OF CONTENTS
4 5
Switzerland – a global pharma hubIf asked about the Swiss economy, people usually first think of banks, chocolate, tourism or watches. These industries are indeed of high importance for the national economy. Yet an industry that is often missing in this list, despite having emerged as one of the leading lights in the Swiss economy over the last century, is the pharmaceuti-cal sector. This publication aims to show the importance of the pharmaceutical industry for the Swiss economy in general and for the region of Basel in particular.
The Swiss pharmaceutical sector is a major employer: More than 40,000 people work directly for the industry. If the indirect work created through ancillary industries is included, as many as 172,000 jobs are related to the phar-maceutical industry. Moreover, it accounts for up to a third of all Swiss exports, and the productivity of the industry is four times as high as that of the economy as a whole. Three big clusters – the Lake Geneva area, the Basel region and Zurich-Zug-Lucerne – account for the lion’s share of the gross value added of the Swiss pharma-ceutical industry.
The Basel region is the pharma hub of Switzerland. Almost two thirds of all employees of the Swiss pharmaceutical industry work in this cluster, and the majority of value added in the pharmaceutical industry is generated in the Basel region. What is more, the industry reinvests much of its earnings in research and development (R&D). This is supported by the fact that R&D expenditure of the Basel region amounts to more than 14 percent of regional GDP – a number far higher than in any other pharma cluster of the world.
The high research intensity directly translates into the number of patent applications filed. In 2011, roughly 170 patents per one million inhabitants were registered by the regional pharmaceutical industry. Again, the Basel region stands out from all other regions in OECD countries. All this has led to a dynamic development of the regional economy. The region’s pharmaceutical industry accounts for four out of every five Swiss francs earned in exports today.
Although it has lost some of its pace in recent years, the Basel region still offers promising growth prospects in the medium and long term: The research institute BAK Basel Economics estimates the annual growth of value added in the regional pharmaceutical industry at about four per-cent up to 2020, which is twice as much as the expected growth for the regional economy as a whole. For this rea-son, the importance of the industry for the Basel region is expected to rise further in the near future, so that it may one day be mentioned along with the other flagship indus-tries of the Swiss economy.
Thomas B. CueniSecretary General Interpharma
PREFACE
6 76
Pharmaceutical industry in Switzerland, including all direct and indirect effects, 2012– nominal GVA: 43 billion CHF– employees: 172 000
PHARMACEUTICAL INDUSTRY IN SWITZERLAND
The pharmaceutical industry impacts the Swiss economy both directly and indirectly. The direct economic impor-tance of the pharmaceutical industry can be measured for example by the number of employees, the value of exports or the gross value added (GVA). The latter is defi ned as the increase in the value of goods resulting from the produc-tion process and is calculated by deducting the value of intermediate goods and services from the total produc-tion value. The GVA of the pharmaceutical industry has grown on average by more than 9 percent annually over the last decade and is thus far higher than the GVA of other industries.
The indirect economic importance of the industry arises from its interdependencies with companies from other industries, from the wage earnings of its employees and from the tax revenue from the companies. All these fac-tors create an additional demand for consumer goods and services, which in turn generate approximately 132,000 jobs in other industries.
9.1%average annual growth rate
of GVA (2000–2012)
4
times more pro-ductive than overall
economy (2012)
24 billion CHF
nominal GVA (2012)
71 billion CHF of
exports (2014)
40 000employees (2012)
Sour
ce: F
SO, P
olyn
omic
s, 2
014.
8 98
Sour
ce: B
AKB
ASEL
, 201
4.
Roughly 75% percent of the gross value added (GVA) in the Swiss pharmaceutical industry in 2012 has been generated by the Basel region, Lake Geneva area and Zurich-Zug-Lucerne.
n Basel regionn Lake Geneva arean Zurich-Zug-Lucerne
n Ticinon Schaffhausenn Valais
SWISS PHARMACLUSTERS
Basel region The pharmaceutical cluster Basel is home to the headquar-ters of pharmaceutical companies steeped in tradition, such as Bayer, Boehringer Ingelheim, Novartis and Roche, as well as the biopharmaceutical company Actelion.
Lake Geneva areaThe cantons of Bern, Fribourg, Geneva, Neuchâtel and Vaud constitute the Lake Geneva cluster and are home to the Swiss branches of Celgene, GlaxoSmithKline, Merck Serono, Sanofi and UCB.
Zurich-Zug-LucerneThe Zurich-Zug-Lucerne cluster has grown into an attrac-tive centre for international life sciences companies and is home to the following companies: AbbVie, Alcon, Amgen, AstraZeneca, Bayer, Biogen, Bristol-Myers Squibb, Gilead, Janssen, Lundbeck, Merck, MSD (Merck Sharp & Dohme), Novartis, Pfizer, Roche and Vifor Pharma.
Schaffhausen-Ticino-ValaisBesides the big pharma clusters, there are three smaller clusters in Switzerland: In Canton Schaffhausen, the phar-maceutical industry plays an important role for the local economy and is based on the activities of Cilag, a subsidi-ary of the pharmaceutical company Janssen that is part of the Johnson & Johnson group. In the Ticino cluster, the pharmaceutical industry has grown historically and now includes several medium-sized companies. Canton of Val-ais plays a strategic role as supplier of chemical inputs for the pharmaceutical production.
11
GROWTH DRIVER PHARMACEUTICALS
Established in the second half of the 19th century, the pharmaceutical industry quickly assumed an important place in the Swiss economy and remains one of the strong-est growth industries to this day. This is due not only to the historical significance of the pharmaceutical industry in the region of Basel, but also to the attractive business environment of Switzerland as a whole.
For the fourth time in succession, Switzerland was ranked first in the Global Innovation Index of the World Intellectual Property Organization (WIPO) in 2014. Switzerland’s capacity for innovation is an essential precondition for a prosperous pharmaceutical industry. Other factors such as tax, accessibility and a large pool of highly trained employees are attracting leading companies in the fields of pharmaceuticals, biotechnology and other related industries to Switzerland.
Thanks to its innovation capacity, the pharmaceutical industry typically achieves an above-average level of pro-ductivity, and the productivity growth rate also usually outstrips that of industry as a whole.
12 13
Major importance of Swiss pharmaceutical industryIn an international comparison of the average value-added growth rate, the Swiss pharmaceutical industry came out top: between 2000 and 2012, the Swiss pharmaceutical industry showed an average annual growth of just over 9 percent, ahead of Germany and the Netherlands and more than twice as high as that of the UK and the USA.
The value added of the Swiss pharmaceutical industry is also impressive as a proportion of the overall economy, with the industry generating almost four percent of Swit-zerland’s total GVA. Even in second-placed Belgium, this proportion is below two percent. The contribution of the pharmaceutical industry to total value added has thus steadily grown over recent years. As a consequence, the importance of the industry for the Swiss economy as a whole has also grown.
GROWTH DRIVER PHARMACEUTICALS
Switzerland
Netherlands
Germany
Denmark
Sweden
UK
USA
France
Italy
* International data according to BAKBASEL database 2013, Swiss data according to ESA 2010.
Sour
ce: B
AKB
ASEL
, 201
4.*
0% 2% 6% 8%4% 10%
Sour
ce: B
AKB
ASEL
, 201
4.*
GROWTH RATE OF VALUE ADDED IN THE PHARMA INDUSTRYAnnual average growth rate per year (in %), 2000 – 2012
Switzerland
Belgium
Germany
Denmark
Italy
USA
Japan
UK
Netherlands
France
0% 1% 3%2% 4%
VALUE ADDED IN PHARMA RELATIVE TO TOTAL ECONOMYShare in %, 2012
9.1
3.9
6.1
1.7
6.0
1.4
4.3
1.1
4.1
0.9
0.8
3.6
0.8
3.2
0.7
1.8
0.6
1.4
0.5
14 15
VALUE ADDED IN PHARMA RELATIVE TO TOTAL ECONOMYShare in %, 1997-2012
Strong dynamism of the Swiss pharmaceutical industryThe nominal gross value added of the Swiss pharmaceuti-cal industry has almost tripled in the past 15 years and stood at around 24 billion Swiss francs in 2012. When adjusted for inflation, the gross value added has actually quadrupled over the same period. And the number of employees has also steadily increased in the last two dec-ades, reaching more than 40,000 for the first time in 2012. While the number of employees working in Switzerland’s pharmaceutical industry accounts for about one percent of all employees in Switzerland, the corresponding value added constitutes almost four percent of the economy as a whole. This ratio reflects above-average productivity of the pharmaceutical industry relative to the overall econ-omy.
GROWTH DRIVER PHARMACEUTICALS
4.0%
3.0%
2.0%
1.0%
0.0%
Sour
ce: F
SO, B
AKB
ASEL
, 201
4.
1209070503019997 11
3.9
Sour
ce: F
SO, B
AKB
ASEL
, 201
4.
131209080706050403020100999897 10 11
40 000
30 000
20 000
10 000
0
EMPLOYEES IN THE SWISS PHARMA INDUSTRYNumber of persons
20 000
15 000
10 000
5 000
0
400
300
200
100
0
Sour
ce: F
SO, B
AKB
ASEL
, 201
4.
1209080706050403020100999897 10 11
VALUE ADDED IN THE SWISS PHARMA INDUSTRYNominal GVA (in m CHF) Real GVA (index, 1997 = 100)
16 17
54% 16% 4% 7% 19%
Relevance of pharmaceutical exportsThe value of pharmaceutical exports has tripled over the past decade and currently stands at 71 billion Swiss francs. At the same time, pharmaceutical exports also accounted for an increasing proportion of Swiss exports overall: in 2014, around one out of three Swiss francs earned through exports was generated by the pharmaceu-tical industry.
Since 2005, exports of pharmaceutical products have increasingly shifted towards the BRIC states – Brazil, Rus-sia, India and China – and to the USA, while the proportion exported to Europe has fallen. The recent crisis in the Eurozone and the strong Swiss franc are likely to be the main reasons for this decrease. Nonetheless, Europe con-tinues to be the most important export market for Swiss pharmaceuticals.
GROWTH DRIVER PHARMACEUTICALS
2005
67% 11% 5% 14%
2000 2014
82%
18%
66%
34%
Pharmaceutical exports Rest
Pharmaceutical exports 22 bn CHF
Pharmaceutical exports 71 bn CHF
Sour
ce: F
CA, B
AKB
ASEL
, 201
5.So
urce
: FCA
, BAK
BAS
EL, 2
015.
Europe USA Japan BRIC Rest
2014
SWISS PHARMA EXPORTSShare of total exports (in %)
SWISS PHARMA EXPORTS ACCORDING TO DESTINATIONSShare of destinations (in %)
3%
18 19
GROWTH DRIVER PHARMACEUTICALS
Switzerland
Boston
Øresund
SF Bay Area
New York
Paris
Milan
London
Munich
Pharma
Energy
Financial sector
Chemicals
Information, communication
Investment goods
Food, tobacco
Total economy
Transport
0 700400300200100
Sour
ce: F
SO, B
AKB
ASEL
, 201
4.
Total economy Life sciences
Sour
ce: F
SO, B
AKB
ASEL
, 201
4.*
300200 250150100500
LABOUR PRODUCTIVITY OF SWISS INDUSTRIESNominal GVA per employee (FTE, in 1 000 CHF), 2012
LABOUR PRODUCTIVITY OF LIFE SCIENCES INDUSTRYNominal GVA per employee (in 1 000 USD PPP), 2012
500 600
626
347
286
200
188
161
157
156
131
* International data according to BAKBASEL database 2013, Swiss data according to ESA 2010.
Competitive thanks to high productivityThe pharmaceutical sector exhibits the highest productiv-ity of all Swiss industries: on average, a worker generates goods worth 626,000 Swiss francs per year, which is about four times as high as the productivity in the overall economy. This high productivity is due to the research intensity and the highly specialized production processes of the pharmaceutical industry.
The productivity of Switzerland’s life sciences industry also holds up exceptionally well when compared with other countries. After correcting for purchasing power, it amounts to 286,000 US dollars, which puts Switzerland in first place. Only the three US clusters Boston, New York and San Francisco Bay Area and also Øresund can some-what keep pace in terms of their labour productivity.
21
The Basel region – Basel-Stadt, Basel-Landschaft and Frick tal – looks back on a long history of innovation-driven economic development. The second half of the 19th cen-tury saw the emergence of the chemical industry as an auxiliary supplier to the textile industry. At the turn of the century, the chemical industry started to produce the first pharmaceuticals in its search for high-value, patentable products and its efforts to circumvent the increasingly unfavourable conditions on the dyestuffs market.
In the 20th century, the pharmaceutical industry quickly developed into an important driver of growth and became the dominant line of business. After a period of diversifica-tion (e.g. agrochemicals) following World War II, the phar-maceutical industry began to refocus on its core business from the 1980s onwards. More recently, biotechnology has become one of the main hopes of the industry’s eter-nal quest for innovation.
Today, more than 25,000 employees work in the pharma-ceutical industry of the Basel region, accounting to 64 per-cent of all employees of the Swiss pharmaceutical indus-try. The pharmaceutical industry of the Basel region also generates the lion's share of value added, and thus con-tributes increasingly to the regional GDP.
BASELREGION
22 23
BASEL REGION
Regional importance of exportsWhereas the life sciences industry is generally important in Switzerland as whole, the Basel region is dominated by the pharmaceutical industry. In Basel-Stadt, 92 percent of all employees of the life sciences industry work for phar-maceutical companies. In Basel-Landschaft and Fricktal this ratio is 59 and 86 percent, respectively.
Moreover, the pharmaceutical industry is the region’s main source for exports. In 2014 the cantons of Basel exported goods and services on the order of 56 billion Swiss francs. Roughly 49 billion (or 87 percent) thereof has been generated by the pharmaceutical industry.
These figures, together with the industry’s share in total employment, underline the paramount importance of the pharmaceutical industry for the Basel region.
Pharmaceutical industry Agrochemical industry R&D in biotechnology Medical technology
0% 10% 20% 30% 60% 70% 80% 100%90%50%40%
Switzerland
Basel-Stadt
55%
16%
5% 8%86%
25%59%
7%
7%92% 10%
36%
2%
1%
1%
2014
Pharmaceuticals Medical devices Agrochemicals Rest
Life sciences exports 50 bn CHF
Sour
ce: F
CA, B
AKB
ASEL
, 201
5.
87%
11%1%1%
COMPOSITION OF THE LIFE SCIENCES INDUSTRYShare in total of employees (in %), 2012
Sour
ce: F
SO, B
AKB
ASEL
, 201
4.
LIFE SCIENCES EXPORTS OF THE BASEL REGIONShare of total exports (in %), excluding Fricktal
Basel-Landschaft
Fricktal
25
Innovation – the introduction of new things, ideas or ways of doing something – is one of the main factors contribut-ing to growth in a modern economy. Especially in knowl-edge-intense sectors, competition is primarily driven by innovation rather than by price. Therefore, innovation is an essential factor for success in the pharmaceutical industry.
Innovation is also an important indicator for the choice of location made by firms. The greater a region’s potential to innovate, the more attractive it appears in international competition with other business locations.
The following section sheds light on factors affecting the Basel region’s innovation capacity. The indicators consid-ered include research and development expenditure, pat-ents and the research quality of the region’s universities.
INNOVATION CAPACITY
26 27
Basel
Boston
Switzerland
Munich
SF Bay Area
Oxford
Paris
New York
Milan
15%10%5%
Basel region leading in patent registrationsThe above-average investment in research and develop-ment in the Basel region is also reflected in a large num-ber of patent registrations in the pharmaceutical domain. In the Basel region, about 170 patents per million inhabit-ants were registered in the pharmaceutical area in 2011. This figure is considerably higher than in other pharma clusters such as Boston, San Francisco or Munich, and five times as much as the Swiss average.
The indicator of patent registrations allows research out-put to be measured rather than research capacity, because it implies the realization of application-oriented and value-generating inventions. The registration process takes up to three years, which explains the time lag in the availability of the indicator.
High investment in research and developmentMeasuring research and development (R&D) spending as a proportion of GDP and comparing it internationally shows the Basel region to be an outlier: at 14 percent of GDP, the Basel region’s investment in R&D is more than double that of Boston and other US-based pharma clus-ters that are well-known internationally for their innova-tion capacity. Moreover, the Basel region’s figure of 14 percent is significantly higher than the Swiss average of just under 5 percent.
The lion’s share of R&D expenditure in the Basel region is financed by the private sector. This fact can be mostly explained by the extensive research activity of the phar-maceutical companies Actelion, Bayer, Novartis and Roche, which are based in the Basel region.
0%
INNOVATION CAPACITY
RESEARCH AND DEVELOPMENT EXPENDITURE Share of regional GDP (in %), 2011
REGISTERED PHARMA PATENTSNumber per million inhabitants, 2011
Sour
ce: F
SO, B
AKB
ASEL
, 201
4.
Private sector expenditure University expenditure Rest
13
12
13.0 1.0
0.7 0.2 0.2
3.3
3.4
3.7
3.6
1.9
1.8
1.1
1.2
1.3
1.3
0.1
0.1
0.5
0.3
0.7
0.6
0.7
0.5
0.4
0.5
0.5
0.1
Basel
Boston
SF Bay Area
Switzerland
Munich
Paris
Milan
New York
London
Sour
ce: O
ECD
PatR
eg, B
AKB
ASEL
, 201
4.
0 20015050 100
91
68
21
20
9
170
33
28 29
High research quality of universitiesThe quantity and quality of academic research attracts specialists from all around the world and creates spillover effects.
According to the Shanghai Index, Switzerland’s universi-ties have been assessed as high-quality institutions. The University of Basel competes with the top universities in Europe and overseas. In the specialized domain of life and agricultural sciences, the index ranks Basel top in Europe along with London and the Swiss average, the latter reflecting the academic strength of the two Federal Insti-tutes of Technology in Lausanne and Zurich.
Shanghai Index: the Academic Ranking of World Universities uses six indicators in four areas (quality of education and per-sonnel, research achievement, size of institution) in order to evaluate more than 1,000 universities world-wide, of which the best 500 are published with their corresponding ranking.
INNOVATION CAPACITY
SF Bay Area
Boston
Munich
Switzerland
London
Basel
Øresund
New York
Paris
SHANGHAI INDEXAverage number of points per university, 2013
Sour
ce: A
RW
U, B
AKB
ASEL
, 201
5.
0 60502010 4030
SPECIALIZED SHANGHAI INDEX IN LIFE AND AGRICULTURE SCIENCESAverage number of points per university, 2013
Sour
ce: A
RW
U, B
AKB
ASEL
, 201
5.
SF Bay Area
Boston
New York
London
Switzerland
Basel
Munich
Øresund
Paris
0 806020 40
72
68
57
53
52
52
48
47
43
52
32
29
26
26
25
25
23
21
31
In the course of globalization, companies are increasingly facing decisions on where best to locate. For this reason, it is essential for a business location to constantly monitor and compare its own inward investment factors with those of other regions.
While costs might play an important part, non-quantifiable factors are also important elements of such decisions. The latter include e.g. the availability of research facilities and international schools and are of great interest for potential employees. The employer, on the other hand, might be more interested in the regulatory framework, such as accessibil-ity, taxation or labour and market regulation.
The innovation-intensive pharmaceutical industry faces a constant need for skilled manpower, such as engineers, IT professionals, marketing specialists and researchers. Today’s highly qualified workforce is increasingly mobile and also takes decisions concerning its living environment. Factors affecting the quality of life are thus becoming increasingly important.
INWARD INVESTMENT FACTORS
32 33
Cambridge
London
Basel
Oxford
Øresund
Munich
Paris
Milan
30%30%
20% 20%
100 105 110 115 120
BAKBASEL Attractiveness IndexInward investment factors substantially influence the growth potential of a region. The Attractiveness Index was developed by BAKBASEL in order to quantify this growth potential and to make it internationally comparable. It includes four of the most important inward investment factors – accessibility, innovation, regulation and taxa-tion – and indexes their scores for each region.
The Basel region compares favourably with other pharma-ceutical industry locations: With a score of slightly more than 111 points, it ranks considerably higher than the average of Western Europe and is on a same level as the prestigious pharma clusters London, Munich and Oxford. The above-average score of the Basel region rests on its attractive taxation system, the liberal regulation of the Swiss market and the excellent innovation capacity of the Basel region.
112.0
116.6
111.4
110.5
109.0
108.8
106.8
100.2
INWARD INVESTMENT FACTORS
Taxation Accessibility Regulation Innovation
COMPOSITION OF THE BAKBASEL ATTRACTIVENESS INDEX
Sour
ce: B
AKB
ASEL
, 201
4.
BAKBASEL ATTRACTIVENESS INDEX Index (100 = average of Western Europe), 2012
Sour
ce: B
AKB
ASEL
, 201
4.
34 35
Measure of taxation (Taxation Index): effective average tax rate that considers all relevant tax rates and rules for an investment of a company or a highly qualified worker.
Attractive taxation systemA region’s taxation system is an important factor not only for companies deciding where to locate their operations, but also with regard to the attractiveness for skilled labour.
Compared internationally, the Basel region’s taxation sys-tem proves to be very attractive: with respect to both tax-ation of companies and highly qualified manpower, the Basel region’s tax burden is markedly lower than that of pharma locations in other countries.
Measure of regulation (Regulation Index): index created using regulation factors elaborated by the OECD and the Fraser Institute (0 = low level of regulation; 6 = high level of regulation).
Low levels of regulationThe intensity of market regulation affects the attractive-ness and the growth perspectives of a business location.
An international comparison of the way labour and prod-uct markets are regulated shows that Switzerland has rel-atively low levels of regulation. Only the Anglo-Saxon coun-tries have even lower levels of regulation, whereas France, Germany and Italy are subject to much stronger regulation in both markets.
3.0
2.0
1.0
0.0
0.50 0.700.60 0.80 1.10 1.201.000.90 1.30
BAKBASEL REGULATION INDEX
0.40
0.30
0.20
0.10
0.20 0.300.25 0.35 0.50 0.550.450.40 0.60
London
MilanØresund
MunichBasel-Stadt
Basel-Landschaft
BostonSF Bay Area
BAKBASEL TAXATION INDEX
New York
Paris
INWARD INVESTMENT FACTORS
REGULATION OF PRODUCT MARKET
Sour
ce: F
rase
r Ins
titu
te, O
ECD
, BAK
BAS
EL,
201
4.
Sour
ce: Z
EW, B
AKB
ASEL
, 201
4.
REGU
LATI
ON O
F LA
BOU
R M
ARK
ET
TAXA
TION
OF
COM
PANI
ES
TAXATION OF HIGHLY QUALIFIED MANPOWER
France
Switzerland
Germany
ItalyEngland
USA
Denmark
36 37
London
Paris
Switzerland
Munich
New York
Basel
Milan
Boston
High number of international schoolsThe availability of international schools is a critical factor in the global competition for highly qualified workers. In order to compare the availability of international schools between the pharma locations, the number of courses offered per million inhabitants has been counted. The Basel region shows the highest number of courses offered per million inhabitants – well above London, New York and marginally more than the Swiss average.
Accessibility Index: indexed measure that quantifies the accessibility of a region. It takes into account the time spent travelling, the frequency of connections and the attractiveness of the destinations (regions are weighted by their GDP).
Availability of international schools: number of courses offered by the International Baccalaureate Organization.
Good accessibility of SwitzerlandWith the advancing integration of global markets, the geo-graphic location and the transportation system are becoming increasingly important in determining a region’s ability to participate in the economic growth process. Accessibility is thus becoming a crucial inward invest-ment factor.
The accessibility of Switzerland comes third after London and Paris, with the Basel region ranking more than 8 per-cent above the Western European average.
100 125120115110105
119.6
118.7
113.4
111.0
110.3
108.6
107.6
106.6
INWARD INVESTMENT FACTORS
Sour
ce: I
VT, B
AKB
ASEL
, 201
4.
BAKBASEL ACCESSIBILITY INDEX Index (100 = average of Western Europe), 2012
AVAILABILITY OF INTERNATIONAL SCHOOLS Number of offered programs per million inhabitants, 2013
Basel
Switzerland
New York
London
SF Bay Area
Boston
Munich
Milan
Sour
ce: I
BO,
BAK
BAS
EL, 2
014.
8.7
8.6
4.5
4.5
3.0
3.0
2.9
1.7
0 10862 4
38 39
Long-term forecasts for the pharmaceutical industry by BAK Basel Economics estimate the annual growth of value added in the Basel region in the period 2015-2020 at 3.7 percent for Basel-Stadt and 4.6 percent for Basel-Land-schaft. This growth rate is significantly higher than the estimated growth rate of the economy as a whole. The reasons for the higher growth potential of the pharmaceu-tical industry can be found in the growing world popula-tion, the increasing middle class and the ageing of the Western population. Last but not least, the high innova-tion capacity in the Basel region and the expansion pro-jects of companies in the Basel region give cause for opti-mism about the future performance of the pharmaceutical industry in the Basel region.
Sour
ce: B
AKB
ASEL
, 201
4.
0% 1% 2% 3% 5%4%
4.2%
3.7%
4.6%
1.8%
1.9%
2.5%
OUTLOOK
Pharma Total economy
LONG-TERM GROWTH FORECASTSEstimated annual growth of GVA, 2015-2020
Switzerland
Basel-Stadt
Basel-Landschaft
40 41
COMPANY PROFILES
ActelionActelion Ltd., with headquarters in Allschwil (BL), is a lead-ing biopharmaceutical company focused on the discov-ery, development and marketing of innovative medicines for diseases where there is a high medical need. Actelion is a pioneer in the field of pulmonary arterial hypertension (PAH). Our PAH portfolio covers the disease spectrum of WHO function classes II to IV and includes medicines for oral, inhalable and intravenous therapy. Actelion also has treatments that are approved by the regulatory authori-ties but not available in all countries for a number of dis-eases that require specialist treatment. These include Gaucher’s disease type 1, Niemann-Pick disease type C, digital ulcerations in patients with systemic sclerosis and also cutaneous T cell lymphoma of the mycosis fungoides type.
www.actelion.com
Bayer in BaselBayer was founded in 1863 and is a leading, global life sciences company today, focusing on innovations in the field of healthcare and food security. Bayer HealthCare Basel (Bayer Consumer Care AG, Basel) is the European headquarters of the global Consumer Care division of the Bayer Group. Basel is home to global functions such as Mar-keting, Research & Development and Product Supply. In addition, the Pharmaceuticals Division and Diabetes Care are also located in Basel. The company employs around 600 people from more than 60 nations in Basel. Today, Bayer employs more than 1,000 people in Zurich, Basel, Muttenz and Zollikofen. We help patients by preventing, relieving and curing diseases as well as improving diagnos-tic methods. And we contribute to the adequate provision of high-quality food and animal feed, as well as renewable plant-based raw materials.
www.bayer.ch
42 43
Boehringer IngelheimBoehringer Ingelheim is a group that maintains global operations with 145 group companies in 50 countries and employs a total of 46,000 people. Boehringer Ingelheim employs around 100 people in Switzerland and is active in the fields of human pharmaceuticals and animal health. The main indications for the products of this family-owned business, which was founded in 1885, are in the areas of respiratory disorders, cardiovascular disease, central nervous system, oncology, metabolic syndrome and viro-logy.
www.boehringer-ingelheim.ch
COMPANY PROFILES
NovartisNovartis is the largest healthcare company in Switzerland and one of the biggest exporters. The company offers a diversified portfolio in order to meet the changing needs of patients and societies as well as possible with innovative medicines, products for eye care and low-cost generic medicines. Novartis is the only company with world lead-ing positions in all these fields. The company was formed in 1996 by the merger of Ciba-Geigy and Sandoz. Novartis operates in more than 140 countries but is rooted in Swit-zerland. The company employs around 130,000 people. Of these, around 13,000 work in Switzerland – spread over a total of nine sites: Basel (BS), Schweizerhalle (BL), Fri-bourg (FR), Geneva (GE), Locarno (TI), Rotkreuz (ZG), Schaffhausen (SH), Schlieren (ZH) and Stein (AG).
www.novartis.ch
44 45
RocheRoche is one of the leading companies in research-based healthcare. It combines the two business areas of Phar-maceuticals and Diagnostics and, as the world’s largest biotech company, it develops medicines in the fields of oncology, immunology, infectious diseases, ophthalmol-ogy and the neurosciences. Roche is the world’s most important supplier of products for in vitro diagnostics and tissue-based cancer tests and a pioneer in diabetes man-agement. The Roche Group, with headquarters in Basel, employs more than 88,500 people worldwide. Basel/Kai-seraugst is one of the largest sites worldwide with around 9,400 employees from more than 90 nations. Roche Pharma (Schweiz) AG in Reinach employs around 130 peo-ple in the areas of marketing and sales, clinical research, regulatory affairs, scientific documentation and medical information.
www.roche.ch
COMPANY PROFILES
46
Publishing informationPublisher:InterpharmaAssociation of research-based pharmaceutical companies in SwitzerlandPetersgraben 35P.O. Box4009 BaselPhone: +41 61 264 34 00E-mail: [email protected]
The content of this brochure can also be found on the website of Interpharma at www.interpharma.ch. Readers are free to download and use the charts in their latest version for their own purposes provided the sources are properly quoted.
Design: Continue AG, BaselPrinted by: Steudler Press, Basel Images: © getty images (cover); © F. Hoffmann-La Roche Ltd (p. 10, 30 and 38); © Niklaus Wächter (p. 20); © Interpharma (p. 24)
Deutsche Originalversion verfügbar
© Interpharma, May 2015
GLOSSARY
ARWU Academic Ranking of World UniversitiesESA European System of Accounts FCA Federal Customs AdministrationFSO Federal Statistical OfficeFTE Full-Time EquivalentGDP Gross Domestic ProductGVA Gross Value AddedIBO International Baccalaureate OrganizationIVT Institute for Transport Planning and SystemsOECD Organisation for Economic Co-operation and DevelopmentPPP Purchasing Power ParityZEW Centre for European Economic Research
Note: The source “BAKBASEL, 2014” refers to data from September 2014.
InterpharmaPetersgraben 35, P.O. BoxCH-4009 BaselPhone +41 (0)61 264 34 00Fax +41 (0)61 264 34 [email protected]
